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Introduction
Bacterial infection is nowadays one of the major causes of
morbidity and mortality not only in developing countries
but globally. Tuberculosis and multi-drug resistant bacteria
are increasing and challenge the diagnostic approaches, the
therapeutic schemes and the control of infection. Early
diagnosis of infection and capacity to distinguish between
bacterial and sterile inflammation is very important to
efficiently treat patients and prevent the complications of
pathology. Most infections are diagnosed by clinical
history, physical examination, laboratory tests, identifica-
tion of pathogens in body fluids and biopsies and by
imaging techniques. There is a substantial difference in the
use of non-nuclear medicine imaging techniques and the
use of radionuclide techniques. The anatomical imaging
techniques such as plain radiography, ultrasonography and
computed tomography are sensitive mainly in chronic
stages of infection when there are significant anatomical
changes. The detection of infection by nuclear medicine
techniques relies on the physiological and biochemical
changes at the site of lesions, which manifest much prior to
the appearance of the anatomical changes.
Nuclear medicine has therefore contributed in the last
years in the development of several radiopharmaceuticals,
used like non-invasive tools, to discriminate between
infection and sterile inflammation. However, none of these
are “infection specific” because sensitivity and specificity
can differ according to the type of infection, to the type of
micro-organism, to the infection site and to the host clinical
conditions/response. The number of micro-organisms avail-
able for targeting seems to be a major discriminating factor
for nuclear medicine techniques. The paper by Akhtar and
colleagues [1], published in this issue of the journal,
describes the relation between bacterial number and
99mTc-UBI 29–41 uptake in mice. This provides important
information about the specificity of this radiopharmaceutical
but disappointingly evidences that it is difficult to discrim-
inate between 2×10
4 and 2×10
6 bacteria, in this model, and
it is probably difficult to image less than 2×10
4 bacteria, at
least in a mouse. The question, therefore, arises about the
minimum number of bacteria that can be detected in vivo,
this being a relevant question to answer before routine
clinical application of bacterial imaging in man.
Radiopharmaceuticals for imaging bacteria
Many radiopharmaceuticals have been reported so far to
detect and locate infection. These are very sensitive but do
not show high specificity in the discrimination between
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e-mail: alberto.signore@uniroma1.itbacterial infection and sterile inflammation. This has been
clearly summarised by Welling and colleagues [2]i na
recent letter in reply to an editorial of G. Lucignani [3].
There is now a wide range of radiolabelled anti-
microbial agents that are undergoing evaluation.
The first group consists of radiolabelled antibiotics such
as
99mTc- or
18F-ciprofloxacin [4–9],
99mTc-sparfloxacin
[10],
99mTc-ceftizoxime [11, 12] and
18F-fleroxacin [13],
anti-fungal agents such as
99mTc-fluconazole and
99mTc-
isoniazid [14] and the anti-Mycobacterium tuberculosis
agent
99mTc-ethambutol [15]. The second group of radio-
pharmaceuticals for imaging infections is derived from the
array of human anti-microbial peptides/proteins that binds
to specific bacterial antigens [16], e.g. peptides derived
from human lactoferrin [17], ubiciquidin (
99mTc or
18F-
UBI) [18–23] and human neutrophil peptide 1–3(
99mTc-
HNP1–3; members of the α-defensins) [24]. In this group,
we can also include bacteriophages that specifically target
bacterial antigens [25]. The third group of radiopharma-
ceuticals is represented by vitamins and bacterial growth
factors that are necessary for bacteria growth as well as for
human cell growth: in particular vitamin H, a group B
vitamin, called biotin, that was labelled with
111In [26].
99mTc-UBI 29–41
The anti-microbial peptides have a wide distribution
throughout the animal and plant kingdom. They are
produced by phagocytes, epithelial and endothelial cells
and other cell types providing protection against microbial
attacks [27]. Their expression is induced upon contact with
micro-organisms or microbial products like lipopolysac-
charides or pro-inflammatory cytokines such as tumour
necrosis factor-α, interferon-γ and interleukin-1 and con-
tributes to the innate resistance to infection. Although
various anti-microbial peptides present different chemical
structures, their mechanism of action is based on the
interaction of the cationic charged domains of the peptides
with the negatively charged surface of the outer membrane
of the bacteria. Microbial membranes expose negatively
charged phospholipids, e.g. lipopolysaccharide or teichoic
acids, on their surface while mammalian cells segregate
into the inner leaflet the lipids with negatively charged
headgroups, thus explaining the poor binding of anti-
microbial peptides to mammalian cells [28, 29]. A range
of human anti-microbial peptides/proteins have been inves-
tigated as radiopharmaceuticals for imaging of infections.
Amongst these,
99mTc-labelled ubiquicidin 29–41 peptide
fragment (
99mTc-UBI) is a cationic human anti-microbial
peptide (MW 1.69 kDa) with the aminoacid sequence Thr-
Gly-Arg-Ala-Lys-Arg-Arg-Met-Gln-Tyr-Asn-Arg-Arg and
has six positively charged residues (5 Arg+1 Lys). In
animal studies,
99mTc-UBI labelled by direct method
showed rapid visualisation of infections with Gram-positive
and Gram-negative bacteria and little accumulation in
sterile inflammation processes.
99mTc-labelled UBI 29–41
preferentially binds to bacteria and fungi in vitro and
accumulates at the site of infection in experimental animal
studies with fast renal clearance with minimal hepatobiliary
excretion and shows the ability to detect infection foci in
humans [20]. As compared to radiolabelled antibiotics, this
radiopharmaceutical shows much lower uptake (as T/B
ratio) in infected lesions and this raises the question
whether this is due to a higher specificity and lower non-
specific binding or whether it is due to the lower number of
molecules bound per bacteria.
Further remarks on studies with radiopharmaceuticals
for imaging bacteria
Given the previous considerations and by reviewing the
literature, it emerges that it is still unclear whether it is
possible to image bacteria in vivo with radiopharmaceuticals,
particularly due to relatively low bacterial mass present in
infection (can be less than 10
6 CFU) and, by consequence,
due to the low number of targeting sites. Indeed, there is very
limited published evidence that radiopharmaceuticals for
bacteria bind to infected sites in a dose-dependent manner
in relation to the number of bacteria. Akthar and colleagues
[1], in this issue of EJNM&MI, try to answer this question
but it is not possible to make a comparison with other
radiopharmaceuticals of this kind. This is due, in part, to the
difficulty of planning similar in vivo experiments, considering
the fast bacterial doubling time in vivo, different biodistribu-
tion, affinity and specific activity of radiopharmaceuticals.
Overall, we lack basic studies to clearly prove the
mechanism of action and binding of these radiopharmaceu-
ticalstobacteria.Asanexample,theuseofinvivodisplacement
studies (typically using large amounts of unlabelled products)
are limited because of bactericidal activity of these compounds
that, in large amounts, may significantly reduce the number of
target sites [30]. Furthermore, since the growth of bacteria is
logarithmic, it is possible to calculate the theoretical number of
bacteria only up to 1 or 2 h after injection in animal models
and therefore the radioactivity associated to bacteria at site of
i n f e c t i o n .I nm a n yp a p e r s ,i m a g e sh a v eb e e na c q u i r e d4ho r
even 24 h after bacterial inoculation.
What is the minimum number of bacteria that we can
image?
In theory, it is possible to calculate the number of labelled
molecules of some radiopharmaceuticals bound to bacteria
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of the molecular weight and specific activity of the
radiopharmaceutical, the number, size and surface-to-
volume ratio of bacteria. The specific activity of most
anti-microbial radiopharmaceuticals can be obtained from
data published by different authors in the literature as well
as the number of bacteria at the time of imaging and the
accumulated radioactivity at the site of injection (Table 1).
Because of the small size of the majority of bacteria that are
no larger than the average of eukaryotic cells (<20 μm), all
bacteria have a large surface-to-volume ratio varying from
about 3:1 (for bacteria with diameter of 2 μm) to 0.3:1 (for
bacteria with diameter of 20 μm). This is an advantage if
the binding site of radiopharmaceuticals is located on the
cell surface. Bacteria volume and mass are more difficult to
calculate and vary according to shape and size of bacteria.
For example, Staphylococcus aureus has an average
volume of about 1.76 μm
3 (0.5–1 μm cell diameter) while
Mycobacterium tuberculosis has a volume of about 8.4 μm
3
(2–4 μm in length and 0.2–0.5 μm in width). The weight of
an average bacterium is reported to be about 5–15×10
−7 g
[31]. Therefore, the available targeting mass of 10
6
S. aureus is about 1.76 mm
3, very small if compared to
the mass of 10
6 granulocytes which is about 1.4 cm
3 (4/
3πr
3 for 14 μm diameter), 1,000-fold more than bacteria.
Despite surface binding sites in bacteria being 10- to 50-
fold more than those present on granulocytes, it is difficult
to believe that we can image such a small mass of bacteria
with the available technology.
If we then calculate the number of bound molecules of
radiopharmaceutical per single bacteria, a wide range of
results appear (Table 1) and this suggests that, at least for
some radiopharmaceuticals, the majority of radioactivity
accumulated at the site of infection is non-specifically
bound to bacteria and is due to the presence of plasma
leakage from capillaries.
Host response to microbial infection
Another aspect that we should consider when attempting to
image bacteria is that infection associated with prosthetic
joints is typically caused by micro-organisms that grow in
biofilms. Within biofilms, micro-organisms are enclosed in
a polymeric matrix and develop into an organised, complex
community with structural and functional heterogeneity. In
the biofilm, microbes are protected from anti-microbial
agents and host immune responses [32, 33]. In these
conditions, the radiolabelled anti-microbial agents cannot
interact with bacteria but only with the extra-cellular matrix
giving information not suitable for specific antibiotic
treatment of the prosthetic infection.
Last but not least, it is necessary to consider the host
response to an infection process. Under the same conditions
(with same number of bacteria), bacteria growth is
dependent on host reaction, particularly on macrophage
and monocyte response. These cells can control infection
spreading in a fast or slow way in accordance with their
number and functionality that change between different
living beings and different tissues and psychological/
metabolic condition of the host. In some cases, associated
oedema and vascular leakage can also be readily induced
by bacterial toxins produced by a very low number of
bacteria (thus increasing the possibility of non-specific
accumulation of radiopharmaceuticals) and, in other cases,
a large number of bacteria may give rise only to a minor
host response. Some radiolabelled anti-microbial agents
Table 1 Calculation of number of living bacteria at 4 h after injection in animal models and activity/bacteria of some radiolabelled anti-
microbials
Radiolabelled
anti-microbial
Specific
activity
(mean)
μCi per
molecule
Type of
bacteria
Calculated no. of bacteria
at site of infection at
time of imaging
a
μCi per
bacteria
b
Calculated bound
molecules per
bacteria
Reference
used for
analysis
99mTc-UBI (29–41) 5 μCi/μg9 × 1 0
−14 S. aureus 2.58×10
8 4.18×10
−9 2,000,000 [1, 22]
99mTc-UBI (29–41) 6.7 μCi/μg4 × 1 0
−16 S. aureus 1.17×10
12 5.1×10
−12 10,000 [21]
99mTc-ciprofloxacin 5 μCi/μg 29.7×10
−20 S. aureus 5×10
8 3.55×10
−8 241×10
8 [8]
99mTc-ciprofloxacin 5 μCi/μg3 2 × 1 0
−20 S. aureus 10
7 1.59×10
−9 105×10
9 [6]
99mTc-sparfloxacin 5.4 μCi/μg4 × 1 0
−15 S. aureus 5.83×10
11 7.4×10
−11 900,000 [10]
99mTc-isoniazid 5.4 μCi/μg1 × 1 0
−15 S. aureus 5.85×10
15 1.6×10
−14 300 [14]
Calculations have been made on the basis of information published by authors and of personal communication in the case of Tc-UBI kindly
provided by Dr. M. Welling
aThis has been calculated using the following formula b=B×2
n, where b is the number of bacteria at time of imaging, B is the number of injected
bacteria (CFU/ml) and n is the number of generations of bacteria, calculated on the basis of time interval occurred between injection and imaging.
The number n is different for each type of bacteria
bThis has been obtained by calculating the ratio between the %ID at site of infection reported in each paper and the number of bacteria at site of
infection at the time of imaging
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[34–37].
From these considerations, it appears that we still need to
investigate many basic aspects to better understand the
mechanisms of binding and accumulation of radiopharma-
ceuticals to bacteria in the hope of finding a specific and
reliable tool for imaging infection that can be used in
clinical settings together or instead of the scintigraphy with
radiolabelled autologous leukocytes or radiolabelled mono-
clonal antibodies to granulocyte antigens.
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